The Institute for Clinical and Economic Review has released a report on lecanemab, an anti-amyloid monoclonal antibody approved by the FDA for the treatment of Alzheimer’s disease. The report found that while lecanemab showed a statistically significant 27% slowing of cognitive decline compared to placebo, there are concerns about the potential harm from amyloid-related imaging abnormalities. The report also found that lecanemab’s annual price of $26,500 exceeds commonly used cost-effectiveness thresholds, and recommended efforts to achieve affordability and access. The report calls for all stakeholders to address health inequities in introducing new treatments for Alzheimer’s disease, and for manufacturers to follow the example of the lecanemab manufacturer in sharing transparent pricing justifications and releasing all patient-level data.
From Skepticism to Support: Healthcare Providers’ Acceptance of Digital Interventions in SUD Treatment in Kenya💡
Healthcare providers in Kenya show high acceptance of digital interventions for substance use disorder treatment. Learn more about how technology is shaping healthcare delivery.
#SyenzaNews #HealthcareInnovation #DigitalInterventions #SubstanceUseDisorder #KenyaHealthcare 🏥💻
📢 #SyenzaNews: The FDA is modernising regulations for AI medical devices with a firm-based approach. This shift focuses on the quality systems of manufacturing firms rather than individual product mechanics.
Discover how this new method can enhance safety and foster innovation in healthcare.
Read more here.
#LifeSciences #HealthcareInnovation #AIMedicalDevices #FDARegulations #HealthTech
Abu Dhabi is making remarkable progress in healthcare through strategic partnerships with leading institutions like CHOP and Penn Medicine. These collaborations aim to advance paediatric oncology, gene therapy, and translational research. 🌍💉
#SyenzaNews #HealthcareInnovation #PaediatricOncology #GeneTherapy #TranslationalResearch #AbuDhabiHealthcare
Read more about how these partnerships are set to transform healthcare in Abu Dhabi and beyond.
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
